MX2019012968A - Nicotinamida de liberacion modificada. - Google Patents
Nicotinamida de liberacion modificada.Info
- Publication number
- MX2019012968A MX2019012968A MX2019012968A MX2019012968A MX2019012968A MX 2019012968 A MX2019012968 A MX 2019012968A MX 2019012968 A MX2019012968 A MX 2019012968A MX 2019012968 A MX2019012968 A MX 2019012968A MX 2019012968 A MX2019012968 A MX 2019012968A
- Authority
- MX
- Mexico
- Prior art keywords
- modified release
- release nicotinamide
- nicotinamide
- hyperphosphatemia
- dyslipidemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
Abstract
La presente invención se refiere a una preparación farmacéutica que comprende nicotinamida de liberación modificada, así como a su uso en un método de prevención y/o tratamiento de niveles elevados de fosfato en suero (hiperfosfatemia) y/o dislipidemia, ambos particularmente resultantes de insuficiencia renal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17168957.3A EP3398600A1 (en) | 2017-05-02 | 2017-05-02 | Modified release nicotinamide |
PCT/EP2018/061202 WO2018202708A1 (en) | 2017-05-02 | 2018-05-02 | Modified release nicotinamide |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019012968A true MX2019012968A (es) | 2020-08-17 |
Family
ID=58664561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019012968A MX2019012968A (es) | 2017-05-02 | 2018-05-02 | Nicotinamida de liberacion modificada. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20180318280A1 (es) |
EP (2) | EP3398600A1 (es) |
JP (1) | JP2020518637A (es) |
KR (1) | KR20190141773A (es) |
CN (1) | CN110913860A (es) |
BR (1) | BR112019022883A2 (es) |
CA (1) | CA3060214A1 (es) |
MA (1) | MA49044A (es) |
MX (1) | MX2019012968A (es) |
RU (1) | RU2019134848A (es) |
WO (1) | WO2018202708A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020235643A1 (en) | 2019-03-14 | 2021-09-30 | Augusta University Research Institute, Inc. | Methods and compositions for supporting renal health |
CN115837023B (zh) * | 2023-02-20 | 2023-05-16 | 中山大学附属第八医院(深圳福田) | 1-甲基烟酰胺在制备抗血管钙化药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1935422A1 (en) * | 2006-12-20 | 2008-06-25 | PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG | Pharmaceutical composition comprising nicotinamide or nicotinic acid |
EP2731609A1 (en) * | 2011-07-14 | 2014-05-21 | APeT Holding B.V. | Nicotinamide compositions and the therapeutic use thereof |
ES2785399T3 (es) * | 2013-06-14 | 2020-10-06 | Conaris Res Institute Ag | Formulación de nicotinamida de liberación prolongada |
HUE048488T2 (hu) * | 2013-12-13 | 2020-07-28 | Conaris Res Institute Ag | Nikotinsavat és/vagy nikotinamidot tartalmazó gyógyászati készítmény a vérlipid szint jótékony hatású befolyására történõ alkalmazásra a bélrendszeri mikrobióta módosításával |
CN104825451A (zh) * | 2015-05-14 | 2015-08-12 | 徐州恒鼎生物科技有限公司 | 一种美白祛斑维生素b3缓释制剂 |
-
2017
- 2017-05-02 EP EP17168957.3A patent/EP3398600A1/en not_active Withdrawn
- 2017-05-16 US US15/596,251 patent/US20180318280A1/en not_active Abandoned
-
2018
- 2018-05-02 CA CA3060214A patent/CA3060214A1/en not_active Abandoned
- 2018-05-02 CN CN201880044413.6A patent/CN110913860A/zh active Pending
- 2018-05-02 KR KR1020197035620A patent/KR20190141773A/ko active Search and Examination
- 2018-05-02 JP JP2019560367A patent/JP2020518637A/ja active Pending
- 2018-05-02 MX MX2019012968A patent/MX2019012968A/es unknown
- 2018-05-02 WO PCT/EP2018/061202 patent/WO2018202708A1/en unknown
- 2018-05-02 EP EP18719613.4A patent/EP3606526A1/en not_active Withdrawn
- 2018-05-02 RU RU2019134848A patent/RU2019134848A/ru not_active Application Discontinuation
- 2018-05-02 MA MA049044A patent/MA49044A/fr unknown
- 2018-05-02 BR BR112019022883A patent/BR112019022883A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP3398600A1 (en) | 2018-11-07 |
MA49044A (fr) | 2020-02-12 |
CN110913860A (zh) | 2020-03-24 |
WO2018202708A1 (en) | 2018-11-08 |
RU2019134848A (ru) | 2021-04-30 |
KR20190141773A (ko) | 2019-12-24 |
EP3606526A1 (en) | 2020-02-12 |
RU2019134848A3 (es) | 2021-04-30 |
JP2020518637A (ja) | 2020-06-25 |
CA3060214A1 (en) | 2018-11-08 |
US20180318280A1 (en) | 2018-11-08 |
BR112019022883A2 (pt) | 2020-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3398948A3 (en) | 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof | |
PH12017501342A1 (en) | Glycan therapeutics and related methods thereof | |
BR112018004620A2 (pt) | moduladores da expressão de kras | |
AU2016261707A8 (en) | Use of cannabis to treat fibromyalgia, methods and compositions thereof | |
WO2017059319A3 (en) | Combination therapy of bromodomain inhibitors and checkpoint blockade | |
TW201614068A (en) | Fucosidase from bacteroides and methods using the same | |
MX2016014807A (es) | Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados. | |
MX2018005829A (es) | Composiciones para tratar el cabello. | |
GB2538178A (en) | Viscosifier polymer for treatment of a subterranean formation | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
MX2014011825A (es) | INHIBIDORES DE ISOXAZOL ß-LACTAMASA. | |
EA033325B1 (ru) | Ингибиторы бромодомена | |
MX2018008402A (es) | Uso de 4-bora-3a,4a-diaza-s-indacenos para fines de seguridad. | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
PH12019501199A1 (en) | Calcium lactate compositions and methods of use | |
PH12016502002B1 (en) | Novel bacteriophage and composition comprising same | |
MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
MX2017014095A (es) | Uso de cd24 para disminuir los niveles de colesterol de las lipoproteinas de baja densidad. | |
MX2017005249A (es) | Compuestos para usarse en el tratamiento antihelmintico. | |
MX2019012968A (es) | Nicotinamida de liberacion modificada. | |
WO2016193941A3 (en) | Testing of a medical fluid treatment system | |
PH12017501735A1 (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
PH12016502322B1 (en) | Compounds and methods for preventing or treating malaria | |
MX2019012970A (es) | Nicotinamida para tratar dislipidemia. | |
MX2017001047A (es) | Compuestos para usar en el tratamiento antihelmintico. |